Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
- Sponsor
- Andres J. M. Ferreri
- Study ID
- NCT01514344
- Phase
- PHASE2
- Status
- Completed
Conditions
- Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- intralesional rituximab — DRUG10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
- supplemental autologous serum — BIOLOGICALpatients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
Study Details
Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.
Key Dates
- Start date
- Dec 31, 2011
- Status verified
- Aug 2022
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2019
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: intralesional rituximab
Primary Outcome Measure
assessment of safety [ Time Frame: During experimental treatment (within 7 months from trial registration) ]